Skip to main content

Table 1 Detailed characteristics of the 23 studies included in the meta-analysis

From: The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis

Publication year Author Nationality Total cases Cancer type Therapy Follow-up (months) PDCD4 expression (cases) Protein location Examine methods Dichotomic criteria Cut-off value Study variables
2003 Chen et al. [22] Germany 124 Lung cancer NA 24 (2–66) 21 NA IHC Positive/negative IHC score = 1 N category, clinical stage, histological differentiation
2007 Mudduluru et al. [28] Germany 71 Colorectal cancer Surgery 36 (1–72) 13 Nucleus and cytoplasm IHC Positive/negative IHC score = 1 OS, DSS
2008 Wang et al. [34] China 43 Ovarian epithelial carcinoma NA 50 (NA) 18 Nucleus and cytoplasm IHC Strong, moderate, weak, negative IHC score = 3 Clinical stage, DSS, histological differentiation
2009 Gao et al. [33] China 84 Glioma Surgery 36 (NA) 16 NA IHC Positive/negative Positive (+) Clinical stage, DSS
Wei et al. [35] China 79 Ovarian invasive ductal carcinoma Surgery + chemotherapy 49 (26–97) 40 Total Western blotting High/low Median DFS
2010 Motoyama et al. [23] Japan 105 Gastric cancer NA 30 (1.2–134.4) 28 NA QPCR High/low T/N ratio = 1 N category, M category, clinical stage, histological differentiation
Reis et al. [29] Canada 50 Oral cancer NA 108 (NA) 25 NA qPCR High/low Median OS, DFS
2011 Lim et al. [19] Korea 108 Colorectal cancer NA NA 64 NA IHC Strong, moderate, weak, negative IHC score = 2 T category, N category, M category, clinical stage, histological differentiation
  Feng et al. [20] China 54 Laryngeal cancer NA NA 33 Nucleus and cytoplasm IHC Positive/negative IHC score = 4 N category, clinical stage, histological differentiation
Kakimoto et al. [50] Japan 19 Gastric cancer NA NA 6 Nucleus or cytoplasm IHC Strong, moderate, weak, negative IHC score = 3 Histological differentiation
2012 Ding et al. [14] China 63 Gastro-intestinal stromal tumor NA NA 21 NA IHC High/low IHC score = 4 Tumor size
Nagao et al. [15] Japan 65 Pancreatic ductal adenocarcinoma NA NA 24 Nucleus or cytoplasm IHC Strong, moderate, weak, negative 30% cancer cells with PDCD4 (+) Tumor size, T category, N category, OS, histological differentiation
Cao et al. [16] Korea 205 Gastric cancer NA NA 136 NA IHC Positive/negative 5% cancer cells with PDCD4 (+) Tumor size
Li et al. [17] China 66 Renal cell carcinoma Surgery 47.3 (18–65) 31 Nucleus & cytoplasm IHC High/low IHC score = 2 Tumor size, T category, M category, OS, histological differentiation
Wang et al. [21] China 60 Laryngeal cancer NA NA 26 NA IHC Positive/negative 30% cancer cells with PDCD4 (+) N category, clinical stage, histological differentiation
  Meric-Bernstam et al. [30] USA 188 Breast cancer Surgery + endocrine therapy 87 (1–197) 78 NA IHC Positive/negative 5% cancer cells with PDCD4 (+) Tumor size
Horiuchi et al. [31] Japan 118 Colorectal cancer NA 45 (2–89) 61 NA qPCR High/low T/N ratio = 1 OS, DFS
2013 Guo et al. [7] China 122 Gastric cancer NA 42 (3–84) 36 NA IHC Positive/negative 6% cancer cells with PDCD4 (+) Tumor size, N category, OS
Zhen et al. [18] China 190 Naso-pharyngeal cancer NA NA (4–126) 73 Cytoplasm IHC High/low IHC score = 5 T category, N category, M category, clinical stage, OS
Qi et al. [24] China 96 Salivary adenoid cystic carcinoma Surgery 42 (3–68) 34 Nucleus and cytoplasm IHC High/low IHC score = 4 Clinical stage, OS, DSS
Ma et al. [26] China 195 Digestive system cancer NA NA 93 Cytoplasm IHC Positive/negative 30% cancer cells with PDCD4 (+) Clinical stage, histological differentiation
2014 Yu et al. [27] China 30 Gastric cancer NA NA 11 NA IHC High/low Stain index score = 6 Histological differentiation
Dou et al. [32] China 92 Advanced rectal cancer Surgery + nCRT 60 (NA) 40 Nucleus and cytoplasm IHC High/low 30% cancer cells with PDCD4 (+) OS, DFS
  1. In total, 2227 solid tumor cases from 23 studies were included in the meta-analysis. The prognostic value of programmed cell death protein 4 (PDCD4) expression in multiple solid tumors was studied, and stratified analysis was performed according to nationality, cancer type, and sample type. The follow-up data are presented as median with range in parentheses
  2. NA not available (not mentioned), IHC immunohistochemistry, OS overall survival, DSS disease-specific survival, DFS disease-free survival, RFS recurrence-free survival, qPCR quantitative polymerase chain reaction, nCRT neoadjuvant chemoradiotherapy